Annual report [Section 13 and 15(d), not S-K Item 405]

SCHEDULE II???VALUATION AND QUALIFYING ACCOUNTS

v3.26.1
SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
 12 Months Ended
Jan. 03, 2026
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
(in thousands)
Description Balance at beginning of period Charged to costs and expenses Deductions Balance at end of period
January 3, 2026
Allowance for sales returns $ 298  $ 7,490  $ 7,467  $ 321 
Allowance for credit losses 221  3  87  137 
Valuation allowance - deferred tax assets 156,105  22,565  —  178,670 
December 28, 2024
Allowance for sales returns $ 420  $ 5,185  $ 5,307  $ 298 
Allowance for credit losses 421  —  200  221 
Valuation allowance - deferred tax assets 137,252  18,853  —  156,105 
December 30, 2023
Allowance for sales returns $ 572  $ 5,552  $ 5,704  $ 420 
Allowance for credit losses 363  112  54  421 
Valuation allowance - deferred tax assets 118,136  19,116  —  137,252